[Daily Medi Reporter Jeongyeon Park]
Gachon University Gil Hospital and the Gachon University Industry-Academic Cooperation Foundation recently signed a technology transfer agreement with RudaCure for a 'pharmaceutical composition for treating corneal damage.'
The technology held by Gachon University Gil Hospital and the Gachon University Industry-Academic Cooperation Foundation is a patented technology for a 'pharmaceutical composition for treating corneal damage containing 8-oxo-2'-deoxyguanosine or a pharmaceutically acceptable salt thereof as an active ingredient,' jointly developed by Professor Donghyun Kim of the Department of Ophthalmology and Director Myunghee Chung of the Gachon Institute of Life Sciences and Medicine.
Unlike existing drugs that merely alleviate dry eye disease, this technology is characterized by fundamentally suppressing the mechanism that causes dry eye disease, giving it high potential for developing treatments for dry eye disease and related ocular conditions.
Director Myunghee Chung of the Gachon Institute of Life Sciences and Medicine stated, "This research is meaningful in that it represents a patented technology for fundamentally treating the growing number of age-related ocular diseases," adding, "We will cooperate with RudaCure to ensure that this technology moves beyond research and translates into outcomes that are truly necessary for patients."
RudaCure, a company developing both protein therapeutics and synthetic drugs for pain and age-related ocular diseases,